Single high dose dry-powder inhaler and method
View Patent ↗A dry-powder inhaler comprising a housing comprising at least one air inlet to a first air passage and a second air passage extending from the first air passage and terminating in a mouthpiece; the housing thereby providing a continuous air passage through the at least one air inlet, the first and second air passages, and the mouth piece; a rigid, fixed, powdered-medicament reservoir comprising a base, the reservoir being associated with the first air passage, and together with the first air passage forming a powder chamber; wherein air passing through the powder chamber travels substantially parallel to an upper surface of the reservoir and powdered-medicament positioned on the base in the reservoir, the upper surface of the reservoir having a surface area, and the reservoir having a volume.
1. A dry-powder inhaler comprising:
a housing comprising at least one air inlet to a first air passage and a second air passage extending from the first air passage and terminating in a mouthpiece; the housing thereby providing a continuous air passage through the at least one air inlet, the first and second air passages, and the mouthpiece;
a rigid, fixed, powdered-medicament reservoir comprising a base, the reservoir being associated with the first air passage, and together with the first air passage forming a powder chamber;
wherein air passing through the powder chamber travels substantially parallel to an upper surface of the reservoir and substantially parallel to powdered medicament positioned on the base in the reservoir, the upper surface of the reservoir having a surface area, and the reservoir having a volume, the surface area being at least 1 cm 2 , and the surface area to volume ratio being at least 1 cm −1 and not more than 10 cm −1 ;
wherein the dry-powder inhaler has a single respirable-dose delivery capability of at least 5 mg of the powdered medicament; and
wherein the dry-powder inhaler has a plurality of entrainment-modulating structures in contact with the powdered medicament in the reservoir.
2. The dry-powder inhaler of claim 1 , wherein the reservoir and powder chamber are elongated along a long axis which is parallel to the flow of air through the first passage; and wherein the reservoir has a length along the long axis and a width perpendicular to the long axis, the length and width defining a length/width aspect ratio of at least 2.5.
3. The dry-powder inhaler of claim 2 , wherein the aspect ratio is at least 3.0.
4. The dry-powder inhaler of claim 1 , wherein the powdered-medicament reservoir has a volume of 0.1 to 5 ml.
5. The dry-powder inhaler of claim 4 , wherein the volume is 0.1 ml to 2.0 ml.
6. The dry-powder inhaler of claim 1 , wherein the upper surface of the reservoir is spaced a distance of at least 1 mm and not more than 3 mm from a top surface of the first air passage.
7. The dry-powder inhaler of claim 1 , wherein the entrainment-modulating structures emerge from the base of the reservoir.
8. The dry-powder inhaler of claim 7 , wherein the entrainment-modulating structures are selected from the group consisting of posts, paddles, baffles, walls parallel to air flow, and a combination thereof.
9. The dry-powder inhaler of claim 1 , wherein an amount of powdered medicament which can be removed from the reservoir during a first 0.5 seconds of air passing through the inhaler is limited to not more than 80% of total powdered medicament removed during an entire inhalation.
10. The dry-powder inhaler of claim 1 , further comprising a deagglomerator associated with the second air passage, associated with the powder chamber, or associated with both the second air passage and the powder chamber and comprising a portion of the continuous air passage.
11. The dry-powder inhaler of claim 10 , wherein the deagglomerator causes deagglomeration of the powder by impacting agglomerates against a surface of the dry-powder inhaler, against other particles contained in the powder, or a combination thereof.
12. The dry-powder inhaler of claim 11 , wherein the deagglomerator is a particle-to-surface impaction deagglomerator.
13. The dry-powder inhaler of claim 10 , wherein the deagglomerator is an S-shaped channel.
14. The dry-powder inhaler of claim 13 , wherein the S-shaped channel has a cross-sectional area that varies along a longitudinal axis of the channel, the cross-sectional area being perpendicular to the longitudinal axis.
15. The dry-powder inhaler of claim 14 , wherein the channel includes at least one convergence and one divergence corresponding to a cross-sectional area decrease of about 15 to about 35 percent and a cross-sectional increase of about 15 to about 35 percent, respectively.
16. The dry-powder inhaler of claim 1 , wherein the inhaler has a single respirable-dose delivery capability of at least 10 mg of the powdered medicament.
17. The dry-powder inhaler of claim 1 , wherein the powdered-medicament reservoir is removable and replaceable.
18. The dry-powder inhaler of claim 1 , wherein the powdered-medicament reservoir contains a removable seal covering the powder in the reservoir prior to use.
19. A method of delivering a single high respirable dose of a powdered medicament to a patient, the method comprising the steps of:
providing the dry-powder inhaler of claim 1 ; and
having a patient inhale through the mouthpiece of the inhaler;
wherein the patient receives a respirable dose of at least 5 mg of the powdered medicament.
20. The method of claim 19 , where during an inhalation the amount of powdered medicament which is removed from the reservoir during the first 0.5 seconds of air passing through the inhaler is limited to not more than 80% of total powder removed during the entire inhalation.